BiotechTube

bezlotoxumab + Vancomycin Oral

ApprovedCompleted
1 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Clostridium Difficile Infection Recurrence

Conditions

Clostridium Difficile Infection Recurrence

Trial Timeline

Jun 25, 2019 → Nov 18, 2021

NCT ID
NCT03880539

About bezlotoxumab + Vancomycin Oral

bezlotoxumab + Vancomycin Oral is a approved stage product being developed by Merck for Clostridium Difficile Infection Recurrence. The current trial status is completed. This product is registered under clinical trial identifier NCT03880539. Target conditions include Clostridium Difficile Infection Recurrence.

What happened to similar drugs?

7 of 20 similar drugs in Clostridium Difficile Infection Recurrence were approved

Approved (7) Terminated (4) Active (13)
✅Fidaxomicin + Vancomycin + PlaceboAstellas PharmaApproved
🔄OPT-80 + vancomycinAstellas PharmaPhase 3
🔄Fidaxomicin oral suspension + Fidaxomicin tablets + Vancomycin oral liquid + Vancomycin capsulesAstellas PharmaPhase 3
✅Fidaxomicin + VancomycinAstellas PharmaApproved
✅Fidaxomicin + VancomycinMerckApproved
🔄fidaxomicin + PlaceboMerckPhase 3
🔄MK-6072 + MK-3415A + Placebo + SOCMerckPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03880539ApprovedCompleted

Competing Products

20 competing products in Clostridium Difficile Infection Recurrence

See all competitors
ProductCompanyStageHype Score
Metronidazole + Metronidazole-DRF1 + Metronidazole-DRF2Dr. Reddy's LaboratoriesPhase 2
32
Fidaxomicin + Vancomycin + PlaceboAstellas PharmaApproved
35
Fidaxomicin + Treatment for CDI other than fidaxomicin TypeAstellas PharmaPre-clinical
26
OPT-80 + vancomycinAstellas PharmaPhase 3
40
Fidaxomicin oral suspension + Fidaxomicin tablets + Vancomycin oral liquid + Vancomycin capsulesAstellas PharmaPhase 3
40
Fidaxomicin + VancomycinAstellas PharmaApproved
43
Fidaxomicin + VancomycinMerckApproved
43
fidaxomicin + PlaceboMerckPhase 3
40
Surotomycin + PlaceboMerckPhase 1
29
CB-183,315 + Placebo + VancomycinMerckPhase 2
35
Surotomycin + PlaceboMerckPhase 1
29
MK-6072 + MK-3415A + Placebo + SOCMerckPhase 3
40
Vancomycin + FidaxomicinMerckApproved
43
FidaxomicinMerckPre-clinical
18
Bezlotoxumab + Standard CDI treatmentMerckPre-clinical
26
MK-3415 + MK-6072 + MK-3415A + Placebo + SOCMerckPhase 3
40
Fidaxomicin + Vancomycin + Matching Placebo to FidaxomicinMerckPhase 3
40
Bezlotoxumab + Placebo + Antibacterial drug treatment (ABD)MerckPhase 3
40
Bezlotoxumab Injection [Zinplava]MerckPre-clinical
26
PAR-101/OPT-80 + VancomycinMerckPhase 3
40